Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (DE:KK3A)
FRANKFURT:KK3A
Holding DE:KK3A?
Track your performance easily
KK3A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€25.20 - €99.50
Previous Close€47
Volume0.00
Average Volume (3M)80.00
Market Cap
€5.56B
Enterprise Value€4.83B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$239.58M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Oct 31, 2024EPS Estimate
-€1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding117,659,578
10 Day Avg. Volume0
30 Day Avg. Volume80
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)50.44
Price to Sales (P/S)1977.01
Price to Cash Flow (P/CF)-15.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.54K
Enterprise Value/Gross Profit-14.97
Enterprise Value/Ebitda-13.95
Forecast
1Y Price Target
€72.19Price Target Upside53.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Cytokinetics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAficamten has delivered impressive datasets in obstructive hypertrophic cardiomyopathy (oHCM) that demonstrate its potential as a best-in-class CMI.
Competitive PositioningCytokinetics' aficamten is well-positioned in the increasingly competitive CMI market.
Regulatory ProgressAnalysts believe aficamten is years ahead of EDG-7500 in terms of development and regulatory progress.
Bears Say
Commercial ViabilityKOLs warned the commercial barriers may be high, with most feeling that SGLT2s would likely receive a Class 1 recommendation in the next guidelines.
Market DifferentiationIt's unclear how differentiated EDG-7500 will be in practice versus Afi.
Safety ConcernsSafety was more problematic, where beyond high rates of GI issues, one patient’s LVEF dropped below 50%, raising the prospect of a potential REMS with negative commercial read-throughs.
---
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was €25.20 and its highest was €99.50 in the past 12 months.
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 31, 2024 which is in 35 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 08, 2024. The company reported -€1.179 earnings per share for the quarter, missing the consensus estimate of -€0.952 by -€0.228.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -€1.11.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 117,659,580 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -€1.179 in its last earnings report, missing expectations of -€0.952. Following the earnings report the stock price went up 7.328%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Fisher Asset Management LLC. It holds Cytokinetics’s shares valued at 29M.
---
Cytokinetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€72.19 (53.60% Upside)
€72.19 (53.60% Upside)
Blogger Sentiment
Bullish
DE:KK3A Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $7.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
75.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.38%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
KK3A Earnings Call
Q2 2024
0:00 / 0:00
---
KK3A Stock 12 Month Forecast
Average Price Target
€72.19
▲(53.60% Upside)
Technical Analysis
Cytokinetics
―
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
FibroGen
―
PTC Therapeutics
―
Best Analysts Covering KK3A
1 Year
1 Year Success Rate
18/25 ratings generated profit
1 Year Average Return
+33.99%
reiterated a buy rating 9 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +33.99% per trade.
---